P-BCMA-101

DB17371InvestigationalCell transplant therapies

P-BCMA-101 is an autologous CAR-T therapy developed using Poseida’s piggyBac platform technology.

Mechanism: Pharmacologically active on Tumor necrosis factor receptor superfamily member 17
Curator reviewed
Code names: P-BCMA-101

Resolves to

Targets

What you can answer from here — as of July 08, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with P-BCMA-101, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.